As immunotherapies and even newer strategies such as antisense therapy march ahead, the drug development pipeline took an interesting turn this year. Here, we look back at the compounds that made the cut, as well as those that got cut.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Drugs that made headlines in 2013. Nat Med 19, 1562–1563 (2013). https://doi.org/10.1038/nm1213-1562
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1213-1562
- Springer Nature America, Inc.